Previously know as In Prime Cellular, in December of 2006, Sentigen Corporation was acquired by Invitrogen Corporation, another SBIR awardee. Sentigen Holding Corp. is a holding company conducting business through two wholly owned operating subsidiaries, Cell & Molecular Technologies, Inc. (CMT) and Sentigen Corp. CMT is comprised of a service organization that provides contract research and development services and a products organization that provides cell culture media, reagents and other research products to companies engaged in the drug discovery process. Sentigen has been engaged in scientific research to develop assays for the screening of G Protein-Coupled Receptors (GPCRs). These assays potentially would have applications in drug discovery, micro-array based detection technologies and environmentally sound pest management solutions for agricultural and human health vectors. CMT specializes in supporting the drug discovery process. CMT's products and services line include high-throughput screening applications, contract research services and the development, production and marketing of specialty cell culture media.